"
Team:SouthBend-Mishawaka-HS-2/Attributions
From 2011.igem.org
(Difference between revisions)
Bmiramontes (Talk | contribs) |
Bmiramontes (Talk | contribs) |
||
| Line 27: | Line 27: | ||
<!-- | <!-- | ||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
/--> | /--> | ||
Revision as of 21:27, 2 June 2011
File:SouthBend-Mishawaka-HS-2 team.png
Your team picture
| Home | Team | Official Team Profile | Project | Parts Submitted to the Registry | Modeling | Notebook | Safety | Attributions |
|---|
Attributions & Contributions
Each team must clearly attribute work done by the team on this page. They must distinguish work done by the team from work done by others, including the host labs, advisors, instructors, graduate students, and postgraduate masters students.
iGEM Heidelberg Mission 2010: miBricks
The great potential of gene therapy is currently limited by two major challenges: tissue specific gene delivery and regulation of gene expression, either dependent on cell-specific properties or intentionally independent of the cellular context. We followed two synergistic tracks to address these problems.
One, we have developed a novel method for miRNA based gene expression tuning in mammalian cells, allowing the fine-tuning of gene expression based on synthetic miRNAs, as well as the cell specific on- and off-targeting based on endogenous miRNAs. We show that this method is functional in vivo and in vitro and prove the high potential of all three miRNA-based regulation approaches.
Two, we have developed a standardized and fast approach towards the creation of AAV-based gene delivery vectors. We have achieved exceptionally selective tissue-specific targeting in vitro and in vivo with hepatocyte specific delivery vectors.
We are happy to provide the synthetic biology community with two high impact innovations which will fuel the improvement of tissue specific gene therapy approaches and other medical applications of synthetic biology.
One, we have developed a novel method for miRNA based gene expression tuning in mammalian cells, allowing the fine-tuning of gene expression based on synthetic miRNAs, as well as the cell specific on- and off-targeting based on endogenous miRNAs. We show that this method is functional in vivo and in vitro and prove the high potential of all three miRNA-based regulation approaches.
Two, we have developed a standardized and fast approach towards the creation of AAV-based gene delivery vectors. We have achieved exceptionally selective tissue-specific targeting in vitro and in vivo with hepatocyte specific delivery vectors.
We are happy to provide the synthetic biology community with two high impact innovations which will fuel the improvement of tissue specific gene therapy approaches and other medical applications of synthetic biology.
